22932 Federal Register / Vol. 87, No. 74 / Monday, April 18, 2022 / Notices 

before making any award in excess of 

the simplified acquisition threshold 

(currently $250,000) over the period of 

performance. An applicant may review 

and comment on any information about 

itself that a Federal awarding agency 

previously entered. The IHS will 

consider any comments by the 

applicant, in addition to other 

information in FAPIIS, in making a 

judgment about the applicant’s integrity, 

business ethics, and record of 

performance under Federal awards 

when completing the review of risk 

posed by applicants as described in 45 

CFR 75.205. 

As required by 45 CFR part 75 

appendix XII of the Uniform Guidance, 

NFEs are required to disclose in FAPIIS 

any information about criminal, civil, 

and administrative proceedings, and/or 

affirm that there is no new information 

to provide. This applies to NFEs that 

receive Federal awards (currently active 

grants, cooperative agreements, and 

procurement contracts) greater than 

$10,000,000 for any period of time 

during the period of performance of an 

award/project. 

Mandatory Disclosure Requirements 

As required by 2 CFR part 200 of the 

Uniform Guidance, and the HHS 

implementing regulations at 45 CFR part 

75, the IHS must require an NFE or an 

applicant for a Federal award to 

disclose, in a timely manner, in writing 

to the IHS or pass-through entity all 

violations of Federal criminal law 

involving fraud, bribery, or gratuity 

violations potentially affecting the 

Federal award. 

All applicants and recipients must 

disclose in writing, in a timely manner, 

to the IHS and to the HHS Office of 

Inspector General all information 

related to violations of Federal criminal 

law involving fraud, bribery, or gratuity 

violations potentially affecting the 

Federal award. 45 CFR 75.113. 

Disclosures must be sent in writing to: 

U.S. Department of Health and Human 

Services, Indian Health Service, 

Division of Grants Management, 

ATTN: Paul Gettys, Deputy Director, 

5600 Fishers Lane, Mail Stop: 09E70, 

Rockville, MD 20857 (Include 

‘‘Mandatory Grant Disclosures’’ in 

subject line), Office: (301) 443–5204, 

Fax: (301) 594–0899, Email: 

Paul.Gettys@ihs.gov 

And 

U.S. Department of Health and Human 

Services, Office of Inspector General, 

ATTN: Mandatory Grant Disclosures, 

Intake Coordinator, 330 Independence 

Avenue SW, Cohen Building, Room 

5527, Washington, DC 20201, URL: 

https://oig.hhs.gov/fraud/reportfraud/ (Include ‘‘Mandatory Grant 

Disclosures’’ in subject line), Fax: 

(202) 205–0604 (Include ‘‘Mandatory 

Grant Disclosures’’ in subject line), or 

Email: 

MandatoryGranteeDisclosures@

oig.hhs.gov 

Failure to make required disclosures 

can result in any of the remedies 

described in 45 CFR 75.371 Remedies 

for noncompliance, including 

suspension or debarment (see 2 CFR 

part 180 and 2 CFR part 376). 

VII. Agency Contacts 

1. Questions on the programmatic 

issues may be directed to: Dr. Marcy 

Ronyak, Director, DCCS, Office of 

Clinical and Preventive Services, 

Division of Clinical and Community 

Services, Indian Health Service, 5600 

Fishers Lane, Mailstop: 08N34–A, 

Rockville, MD 20857, Phone: (301) 443– 

6458, Fax: (301) 594–6213, Email: 

Marcella.Ronyak@ihs.gov. 

2. Questions on grants management 

and fiscal matters may be directed to: 

Donald Gooding, Grants Management 

Specialist, Indian Health Service, 

Division of Grants Management, 5600 

Fishers Lane, Mail Stop: 09E70, 

Rockville, MD 20857, Phone: (301) 443– 

2298, Email: Donald.Gooding@ihs.gov. 

3. Questions on systems matters may 

be directed to: Paul Gettys, Deputy 

Director, Division of Grants 

Management, Indian Health Service, 

Division of Grants Management, 5600 

Fishers Lane, Mail Stop: 09E70, 

Rockville, MD 20857, Phone: (301) 443– 

2114; or the DGM main line (301) 443– 

5204, Email: Paul.Gettys@ihs.gov. 

VIII. Other Information 

The Public Health Service strongly 

encourages all grant, cooperative 

agreement, and contract recipients to 

provide a smoke-free workplace and 

promote the non-use of all tobacco 

products. In addition, Public Law 103– 

227, the Pro-Children Act of 1994, 

prohibits smoking in certain facilities 

(or in some cases, any portion of the 

facility) in which regular or routine 

education, library, day care, health care, 

or early childhood development 

services are provided to children. This 

is consistent with the HHS mission to 

protect and advance the physical and 

mental health of the American people. 

Elizabeth A. Fowler, 

Acting Director, Indian Health Service. 

[FR Doc. 2022–08249 Filed 4–15–22; 8:45 am] 

BILLING CODE 4165–16–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Phase II SBIR Topic 107. 

Date: May 24, 2022. 

Time: 9:30 a.m. to 11:30 a.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Rajiv Kumar, Ph.D., 

Branch Chief, Blood and Vascular Branch, 

Office of Scientific Review, National Heart, 

Lung and Blood Institute, National Institutes 

of Health, 6705 Rockledge Drive, Room 208– 

W, Bethesda, MD 20892, (301) 435–0270, 

rajiv.kumar@nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Systems Biology and Pulmonary Disease. 

Date: May 27, 2022. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Shelley S. Sehnert, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 208–T, 

Bethesda, MD 20892–7924, (301) 827–7984, 

ssehnert@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: April 12, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08202 Filed 4–15–22; 8:45 am] 

BILLING CODE 4140–01–P 


khammond on DSKJM1Z7X2PROD with NOTICES